(VIANEWS) – TPG Specialty Lending (TSLX), Gilead Sciences (GILD), Elbit Systems Ltd. (ESLT) are the highest payout ratio stocks on this list.

We have collected information regarding stocks with the highest payout ratio at the moment. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.

When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. TPG Specialty Lending (TSLX)

99.39% Payout Ratio

Sixth Street Specialty Lending, Inc. is a company that specializes in business development. This fund offers senior secured loans (first, second, and unitranche), as well as unsecured loans and mezzanine loans. It also invests in equity securities, corporate bonds, structured products and non-control structured capital. The focus is on co-investments to support organic growth, product or market expansion, restructuring initiatives and recapitalizations. It invests in software and technology, business services, retail, health, energy, computing, consumer & industrial, manufacturing, industrials. Royalty-related businesses, education, specialty finance, and other areas. The fund primarily focuses on financing and lending middle-market companies based in the United States. This fund invests in businesses with an enterprise value of $50 million to $1 billion, and EBITDA between $10million and $250 million. Transaction sizes range from $15 million to $350 million. It can invest across all capital structures and arrange syndicated transactions up to $500,000,000.

Earnings Per Share

As for profitability, TPG Specialty Lending has a trailing twelve months EPS of $1.65.

PE Ratio

TPG Specialty Lending has a trailing twelve months price to earnings ratio of 9.9. Meaning,
the purchaser of the share is investing $9.9 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.07%.

Yearly Top and Bottom Value

TPG Specialty Lending’s stock is valued at $16.34 at 20:23 EST, way below its 52-week high of $24.74 and above its 52-week low of $16.09.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.7%, now sitting on 280.84M for the twelve trailing months.

2. Gilead Sciences (GILD)

79.89% Payout Ratio

Gilead Sciences, Inc. is a biopharmaceutical firm that discovers, develops, commercializes and markets medicines in areas where there are unmet medical needs in America, Europe, and around the world. Biktarvy and Genvoya products are available. The company also sells Yescarta and Tecartus products, Trodelvy and Zydelig for cell therapy and hematology patients. The company also offers Letairis, an oral treatment for pulmonary arterial hypertension, Ranexa, an oral treatment for chronic angina, and AmBisome which is a liposomal treatment for serious invasive fungal infections. Gilead Sciences, Inc. is a member of the following collaborations: Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., Inc., Inc., Inc. It was founded in 1987, and has its headquarters in Foster City.

Earnings Per Share

As for profitability, Gilead Sciences has a trailing twelve months EPS of $0.24.

PE Ratio

Gilead Sciences has a trailing twelve months price to earnings ratio of 256.92. Meaning,
the purchaser of the share is investing $256.92 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.1%.

Moving Average

Gilead Sciences’s worth is below its 50-day moving average of $63.31 and under its 200-day moving average of $63.54.

Sales Growth

Gilead Sciences’s sales growth is negative 5.7% for the current quarter and negative 20.1% for the next.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 18.2% and a negative 42.3%, respectively.

3. Elbit Systems Ltd. (ESLT)

36.43% Payout Ratio

Elbit Systems Ltd. designs and produces a range of land-, airborne and naval systems, as well as products, primarily for defense and homeland security. It offers commercial and military helicopter systems, as well as commercial and unmanned aviation systems. The company also supplies electro-optic and night vision systems, countermeasures and systems for naval and land systems. The company also produces and sells radio communications equipment and data links, cyber intelligence, homeland security solutions, laser products, guided rocket systems, and armored vehicles and other platforms protection and survivability systems. It also provides training and support services. It markets its products and systems as either a prime contractor, subcontractor or supplier to different governments and businesses. The company has also operations throughout the United States and Europe. It was founded in Israel in 1966.

Earnings Per Share

As for profitability, Elbit Systems Ltd. has a trailing twelve months EPS of $5.27.

PE Ratio

Elbit Systems Ltd. has a trailing twelve months price to earnings ratio of 37.53. Meaning,
the purchaser of the share is investing $37.53 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.46%.

Yearly Top and Bottom Value

Elbit Systems Ltd.’s stock is valued at $197.76 at 20:23 EST, way below its 52-week high of $244.59 and way higher than its 52-week low of $142.20.

4. Invesco (IVZ)

30.19% Payout Ratio

Invesco Ltd., a public investment manager is owned by the company. It provides services for retail clients as well as institutional clients and high-net-worth clients. The firm manages client-specific equity and fixed income portfolios. It also offers equity, fixed income and commodity mutual funds to its clients. The firm launches fixed income, equity and multi-asset funds as well as balanced exchange-traded funds. It also manages and launches private funds. The firm invests in fixed and public equity markets around the world. It also invests in other markets such as currencies and commodities. It invests in large-cap, small-cap and mid-cap growth stocks. The firm also invests in fixed income, including convertibles, government bonds and municipal bonds. The firm also invests short-term and intermediate-term bonds, high-yield bonds, tax-free and taxable bonds, senior secured loans and structured securities like asset-backed security, commercial mortgage-backed Securities, and mortgage-backed Securities. It employs long/short, absolute return and global macro strategies. To make investments, it uses quantitative analysis. The company was previously known as Invesco plc.

Earnings Per Share

As for profitability, Invesco has a trailing twelve months EPS of $1.53.

PE Ratio

Invesco has a trailing twelve months price to earnings ratio of 8.96. Meaning,
the purchaser of the share is investing $8.96 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.6%.

Volume

Today’s last reported volume for Invesco is 3998360 which is 11.49% below its average volume of 4517810.

Sales Growth

Invesco’s sales growth is negative 6.4% for the present quarter and negative 8.9% for the next.

LEAVE A REPLY

Please enter your comment!
Please enter your name here